WW International

WW International reduced debt from about $1.6bn to just above $400m, halving interest expense and expects to be free-cash-flow positive this year while reinvesting in growth. Clinical subscribers rose nearly 56% in Q2 and the company projects clinical revenue will reach 25%–30% of total revenue in 2026 as GLP-1 telehealth offerings expand. Management guided 2026 revenue of $620m–$635m and adjusted EBITDA of $105m–$115m, increased marketing to raise GLP-1 awareness and expanded partnerships including Sam's Club and LillyDirect. Adjusted gross margins remain near 73% and the company highlighted app enhancements and behavioral programs to differentiate its services. » More on finance.yahoo.com

WW International shares climbed 3.1% after the close to $17.21, continuing their recovery from the 52-week low despite no new company-specific news. Drivers were strong Q2 results (EPS $1.41 vs. $0.89 consensus), a confirmed full-year revenue guide of $620–635 million, and 32% revenue growth in the clinical subscriptions segment. Additional support came from insider purchases and the disclosure of roughly an 8.4% stake by an activist investor, while thin after-hours volume and the micro-cap structure amplified the price move. » More on de.investing.com

Wolverine World Wide will pay a quarterly cash dividend of $0.10 per common share, payable on August 3, 2026 to shareholders of record on July 1, 2026. The payment matches the prior quarter and implies an annualized dividend of $0.40 per share with a dividend yield of 2.38%. The company has maintained dividend payments for 39 consecutive years; the stock is trading at $17.26 and is rated undervalued by InvestingPro. » More on de.investing.com